Research and Development

Showing 15 posts of 9594 posts found.

Sanofi workers strike in France

January 7, 2011 Research and Development, Sales and Marketing Sanofi, Sanofi-Aventis, strikes, unions

Sanofi-Aventis workers have gone on strike in France as the company looks to cut jobs. Nine unions representing workers at …
Avastin (bevacizumab) packs

Study highlights Avastin heart failure risk

January 6, 2011 Research and Development, Sales and Marketing Roche, avastin, bevacizumab, breast cancer

A new study confirms that Roche’s Avastin is linked to a small but significant increased risk of heart failure in …

Biogen Idec appoints new head of R&D

January 6, 2011 Research and Development, Sales and Marketing Biogen IDEC, Douglas Williams, Steven Holtzman, appointment, research and development, sales and marketing

Biogen Idec has a new head of research and development, appointing Douglas Williams to oversee its global operations. The position …

Merck KGaA opens outsourcing centre in India

January 5, 2011 Research and Development Application and Technology Centre, India, Merck KGaA, Merck Millipore, Millipore, outsourcing

Merck KGaA has opened a new technology centre near Mumbai in India that will offer a range of research services …

Contract research news in brief

January 5, 2011 Research and Development Accel Synthesis, Almac, Bioanalytical Systems, Caliper Life Sciences, Cambridge Research & Instrumentation, Critical Path Services, Pharmasset, ReSearch Pharmaceutical Services, ResourcingPoint, Warburg Pincus

Private equity firm Warburg Pincus buys RPS for $227 million, plus updates from BASi, Almac, Caliper, and Critical Path Services/Accel …

EDC is Now – The Changing

January 5, 2011 Research and Development

Clinical research is rapidly moving toward the electronic environment as more  han half of all studies are conducted utilizing EDC, …

GSK’s Dr Anne Phillips moves to Novo Nordisk

January 4, 2011 Research and Development, Sales and Marketing Dr Anne Phillips, Novo Nordisk, apppointment, research and development, sales and marketing

Novo Nordisk has appointed Dr Anne Phillips as vice president for clinical, medical and regulatory affairs for North America. She …

Achieve More in Phase I Studies

January 4, 2011 Research and Development

Some individuals believe not much has changed in Phase 1 dose escalation studies. A recent review1 that looked at 105 …
Novartis Holly Springs

Novartis adds R&D unit to new vaccines plant

December 31, 2010 Manufacturing and Production, Research and Development Novartis, pharma manufacturing, vaccines

Swiss drugmaker Novartis is planning to spend $36 million to set up an R&D laboratory on the site of its …

VTE trial boost for Pfizer and BMS’ apixaban

December 31, 2010 Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Pfizer, VTE, apixaban, enoxaparin, venous thromboembolism

Pfizer and Bristol-Myers Squibb’s oral anticoagulant apixaban has shown benefits over a standard injectable treatment for venous thromboembolism in a …

2010: Pharma’s year in review

December 23, 2010 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2010, Avandia, China, European healthcare spending, GSK, Obama, year in review

2010 saw a harsh new economic reality dominate decisions in the US and Europe, but pharma seized on opportunities in …

Gilead set to acquire Arresto for $225 million

December 23, 2010 Research and Development AB0024, Arresto, Cancer, Gilead, advanced solid tumours, ambrisentan, fibrotic diseases, idiopathic pulmonary fibrosis

Gilead Sciences is set to acquire fellow California, US-based biotech Arresto for $225 million to bolster its early stage pipeline. …

AstraZeneca takes $445m hit to halt motavizumab

December 22, 2010 Research and Development AZ, AstraZeneca, MedImmune, motavizumab, respiratory, respiratory syncytial virus

AstraZeneca has withdrawn a US licence application for its biologic respiratory treatment motavizumab in a move that will cost the …

Novartis blood cancer drug impresses in late stage trial

December 22, 2010 Research and Development, Sales and Marketing INC424, Novartis, blood cancer, myelofibrosis, orphan drug

Novartis has released positive phase III results of its myelofibrosis drug INC424 showing it met its primary endpoint of reducing …
The Gateway to Local Adoption Series

Latest content